Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    

INC RESEARCH HOLDINGS INC
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Rosen Law Firm Announces Investigation of Securities Claims Against INC Research Holdings, Inc. – INCR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:04pm CEST

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) resulting from allegations that INC Research may have issued materially misleading business information to the investing public.

On August 1, 2017, INC Research and inVentiv Health, Inc. (“inVentiv Health”) announced the completion of a merger between the two companies. On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. On this news, shares of INC Research fell $16.35 per share or over 28% from its previous closing price to close at $41.15 per share on November 9, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by INC Research investors. If you purchased shares of INC Research, please visit the firm’s website at http://www.rosenlegal.com/cases-1236.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
12:32pSYNEOS HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
12:21pSyneos Health™ Acquires Kinapse to Further Enhance End-to-End Capabilit..
GL
08/17Syneos Health to Present at the 2018 Baird Global Healthcare Conference
GL
08/17SYNEOS HEALTH : PAREXEL Announces Appointment of Two Key Executives
AQ
08/08SYNEOS HEALTH, INC. : Entry into a Material Definitive Agreement, Financial Stat..
AQ
08/08SYNEOS HEALTH : Announces Pricing of Secondary Offering of Common Stock
AQ
08/07SYNEOS HEALTH : Announces Secondary Offering of Common Stock
AQ
08/07Syneos Health Announces Pricing of Secondary Offering of Common Stock
GL
08/06Syneos Health Announces Secondary Offering of Common Stock
GL
08/03SYNEOS HEALTH, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News from SeekingAlpha
01/03INC Research CFO exiting post at April's end 
2017INC Research Holdings 2017 Q3 - Results - Earnings Call Slides 
2017INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca.. 
2017Midday Gainers / Losers 
2017INC Research misses by $0.08, misses on revenue 
Financials ($)
Sales 2018 4 457 M
EBIT 2018 516 M
Net income 2018 33,1 M
Debt 2018 2 558 M
Yield 2018 -
P/E ratio 2018 149,19
P/E ratio 2019 33,39
EV / Sales 2018 1,66x
EV / Sales 2019 1,49x
Capitalization 4 861 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,1 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Alistair John Macdonald Chief Executive Officer & Director
Michael A. Bell Chairman
Jason Michael Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-5.39%4 861
CELLTRION, INC.--.--%29 483
IQVIA HOLDINGS INC22.86%24 367
LONZA GROUP17.93%23 220
INCYTE CORPORATION-27.36%14 625
SEATTLE GENETICS, INC.39.51%11 852